MENU

Organoids: A Revolutionary New Tool for Drug Screening

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, Scientific Engagement, Crown Bioscience, Inc.
    Biography
      Rekha is a trained cancer biologist with a focus on preclinical cancer therapeutics, immune-oncology, cancer signaling, and tumor microenvironment. She earned her Ph.D. in Biochemistry from Central Drug Research Institute, India.
      She joined the University of Pittsburgh as a postdoctoral researcher and moved onto research faculty. She has extensively worked in stem cell biology and translational cancer research using patient's blood, tumor and bone marrow samples with a correlation of clinical data for the targeted biomarker identification with the drug treatment.
      She joined National Surgical Adjuvant Breast and Bowel project (NSABP), a clinical trial supportive group to develop strategies for preclinical evaluation of test agents to support NSABP's phase I/II clinical trials for colon and breast cancer. She also led the effort of organoids generation from the PDX tumor tissue to screen drug or drugs combination as personalized medicine. Rekha represented NSABP as a translational research committee member on B-50 Katherine-B027938 Roche study.
      Rekha role at CrownBio is to direct scientific engagement with pharmaceutical company, academic scientists, and clients. She helps in decision making with goal of high scientific input in study design and model execution. Exchange scientific information for existing and new opportunities between BD and the scientific team, generate protocols, study designs and proposals to define projects/ studies.

    Abstract

    “The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo genetic drift over time due to adapting to in vitro growth, thus showing limited relevance to the human disease. Interpatient tumor heterogeneity is also a major hurdle with standard in vitro models failing to recapitulate this variability. Patient-derived xenografts are the gold standard preclinical models for their proven translatability to the human disease but can be costly and time consuming to generate and maintain. The Hubrecht Organoid Technology (HUB) has pioneered the development of tumor organoids, a revolutionary patient-derived 3D in vitro system that recapitulates the genomic, morphological, and pathophysiological characteristics of their parental tumor. HUB organoids provide highly clinically relevant 3D in vitro models for oncology drug development. To overcome the limitation imposed by sourcing patient material for organoid preclinical development PDX can be used as a source of human tumor tissue leading to a patient-relevant matched in vitro/in vivo platform for oncology drug screening.”

    Learning bullets:
    1. Find out why HUB organoids are considered best in class systems
    2. Understand how organoids are revolutionizing oncology drug development
    3. Learn about how patient-derived xenografts (PDX) can be leveraged to develop the largest organoid library for oncology drug discovery


    Show Resources
    You May Also Like
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    OCT 29, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    Loading Comments...
    Show Resources
    Attendees
    • See more